Leiden, the Netherlands – In a recent open label clinical study Lozano and co-workers investigated the effect of subcutaneous specific immunotherapy...
LEIDEN - the Netherlands – HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II trial with SUBLIVAC®...
LEIDEN - the Netherlands – HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II trial with SUBLIVAC®...
LEIDEN - the Netherlands – HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II dose range finding...
HAL Allergy uses cookies to optimize the design of this website and make continuous improvements. By continuing your visit the website, you consent to the use of cookies.
Accepting cookies makes our websites easier to navigate, lets you find what you are looking for faster, and helps us show you information that is more relevant and ads that are more likely to be of interest to you. Do you accept cookies?